Report of the Second Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Arch. Intern. Med., 140: 1280, 1980.
2.
Humphreys, G.S. , Delvin, D.G.: Ineffective-ness of propranolol in hypertensive Jamaicans. Br. Med. J., 2: 601, 1968.
3.
Hollifield, J.W., Sherman, K., Slaton , P.G.: Age, race and sex as a determinant of successful antihypertensive therapy. Prev. Med., 7: 111, 1978.
4.
Moser, M., Hale, M., Morgan, R., et al.: Epidemiology of hypertension with particular reference to the Bahamas (Part 1). Am. J. Cardiol., 4: 727, 1959.
5.
Finnerty, F.A. , Maxwell, M.H., Lunn , J., et al.: Long-term effects of furosemide and hydrochlorothiazide in patients with essential hypertension: A two-year comparison of efficacy and safety. Angiology, 28: 125, 1977.
6.
Zacharias, F.J. , Cowan, K.J., Prestt , J., et al.: Propranolol in hypertension. A study of long-term therapy 1964-1970. Am. Heart J., 83: 755, 1972.
7.
Benson, M.K. , Berrill, W.T., Cruickshank , J.W., et al.: A comparison of four beta adrenoreceptor antagonists in patients with asthma. Br. J. Clin. Pharmacol. , 5: 415, 1978.
8.
Carruthers, S.G., Shanks, R.G., McDevitt , D.G.: Intrinsic heart rate on exercise and the measurement of beta adrenoreceptor blockade. Br. J. Clin. Pharmacol., 3: 991, 1976.
9.
Morgan, T.O. , et al.: The use of pindolol (Visken) in the treatment of hypertension. Med. J. Aust., 2: 309, 1972.
